Literature DB >> 22843613

Pharmacodynamics of oxytetracycline administered alone and in combination with carprofen in calves.

C Brentnall1, Z Cheng, Q A McKellar, P Lees.   

Abstract

The pharmacodynamics (PD) of oxytetracycline was investigated against a strain of Mannheimia haemolytica. In vitro measurements, comprising minimum inhibitory concentration (MIC), minimum bactericidal concentration and time-kill curves, were conducted in five matrices; Mueller Hinton Broth (MHB), cation-adjusted MHB (CAMHB) and calf serum, exudate and transudate. MICs were much higher in the biological fluids than in MHB and CAMHB. Ratios of MIC were, serum: CAMHB 19 : 1; exudate:CAMHB 16.1; transudate:CAMHB 14 : 1. Ex vivo data, generated in the tissue cage model of inflammation, demonstrated that oxytetracycline, administered to calves intramuscularly at a dose rate of 20 mg/kg, did not inhibit the growth of M haemolytica in serum, exudate and transudate, even at peak concentration. However, using in vitro susceptibility in CAMHB and in vivo-determined pharmacokinetic (PK) variables, average and minimum oxytetracycline concentrations relative to MIC (C(av)/MIC and C(min)/MIC) predicted achievement of efficacy for approximately 48 hours after dosing. Similar C(av)/MIC and C(min)/MIC data were obtained when oxytetracycline was administered in the presence of carprofen. PK-PD integration of data for oxytetracycline, based on MICs determined in the three biological fluids, suggests that it possesses, at most, limited direct killing activity against M haemolytica. These data raise questions concerning the mechanism(s) of action of oxytetracycline, when administered at clinically recommended dose rates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22843613     DOI: 10.1136/vr.100935

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  6 in total

1.  Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats.

Authors:  Emilio Fernández-Varón; Carlos Cárceles-García; Juan Manuel Serrano-Rodríguez; Carlos M Cárceles-Rodríguez
Journal:  BMC Vet Res       Date:  2016-10-13       Impact factor: 2.741

2.  What is the true in vitro potency of oxytetracycline for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida?

Authors:  L Dorey; S Hobson; P Lees
Journal:  J Vet Pharmacol Ther       Date:  2017-01-18       Impact factor: 1.786

3.  Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens.

Authors:  Lucy Dorey; Peter Lees
Journal:  BMC Vet Res       Date:  2017-06-23       Impact factor: 2.741

4.  Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.

Authors:  Lucy Dorey; Ludovic Pelligand; Peter Lees
Journal:  BMC Vet Res       Date:  2017-07-01       Impact factor: 2.741

5.  Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.

Authors:  L Dorey; L Pelligand; Z Cheng; P Lees
Journal:  J Vet Pharmacol Ther       Date:  2017-01-16       Impact factor: 1.786

6.  PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin against Streptococcus suis in Piglets.

Authors:  Anxiong Huang; Feng Mao; Lingli Huang; Shuyu Xie; Yuanhu Pan; Wei Qu; Guyue Cheng; Zhenli Liu; Zonghui Yuan; Dapeng Peng; Haihong Hao
Journal:  Antibiotics (Basel)       Date:  2022-02-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.